Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU) Expected data in H2 2022 brings Synlogic to three clinical readouts this year Third candidate in less than two years to enter the clinic; Reflects productivity of Synthetic Biotic platform ...

Synlogic Announces Appointment of General Counsel and Corporate Secretary CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...

Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1618 for the Treatment of Phenylketonuria CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...

Synlogic Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update - Phenylketonuria (PKU) program on track for Phase 3 trial initiation in H2 2022 – - Clinical readouts anticipated for PKU program in H1 2022 and in homocystinuria and enteric hyperoxaluria in H2...

Synlogic Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...